Bristol Myers Squibb, Princeton, NJ, United States.
Future Oncol. 2023 Jan;19(3):229-244. doi: 10.2217/fon-2022-0801. Epub 2023 Mar 28.
The benefit of pathologic complete response (pCR) in early breast cancer (eBC) is not well described in the real-world setting. This study used the nationwide Flatiron Health electronic health record-derived deidentified database to describe treatment patterns and survival outcomes by pCR status after neoadjuvant therapy (NAT) in women with triple-negative or HR/HER2 eBC. Observational cohort study analyzing women with eBC who started NAT between 2011 and 2018. 496 women were included in the study; of those, 16.1% achieved pCR, of which 35.7% were triple-negative and 6.1% were HR/HER2 eBC. More women with triple-negative eBC (95.2%) were exclusively treated with chemotherapy-based NAT versus HR/HER2 eBC (56.1%). In multivariate analyses from NAT start, not achieving pCR was associated with increased risk of death and progression. pCR status may be a reliable prognostic indicator for survival in these eBC subtypes in the real-world setting.
在真实世界环境中，早期乳腺癌（eBC）患者病理完全缓解（pCR）的获益情况尚未得到充分描述。本研究利用全国范围内的 Flatiron Health 电子健康记录衍生的去识别数据库，描述了三阴性或 HR/HER2 eBC 女性接受新辅助治疗（NAT）后 pCR 状态的治疗模式和生存结局。这是一项观察性队列研究，纳入了自 2011 年至 2018 年期间开始接受 NAT 的 eBC 女性。共纳入 496 名女性；其中，16.1%达到了 pCR，其中 35.7%为三阴性，6.1%为 HR/HER2 eBC。与 HR/HER2 eBC（56.1%）相比，更多的三阴性 eBC 女性（95.2%）仅接受基于化疗的 NAT 治疗。从 NAT 开始的多变量分析显示，未达到 pCR 与死亡和进展风险增加相关。在真实世界环境中，pCR 状态可能是这些 eBC 亚型生存的可靠预后指标。
